NCCS and tech firm to collaborate on Asian-prevalent cancer research
The deal will speed up translational cancer research over the next two years.
The National Cancer Centre Singapore (NCCS) and Agilent Technologies inked a research collaboration agreement to work on translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.
The agreement includes “the supply of an Agilent Magnis Next-Generation Sequencing (NGS) Preparation System to help investigate details specific to Asian cancer cohorts, where tissue samples derived from routine clinical care remain limited locally and regionally.”
Agilent's fully automated NGS library preparation platform, with its installation at Singapore's Cancer Discovery Hub (CDH), seeks to deliver reproducible results by simplifying an assay of multiple genes and complex genetic aberrations from genomic DNA.
The research work focuses on better characterising tumor genomes and advancing the use of this data in patient care to transform clinical trials and diagnostics in oncology and improve treatment decisions.
Agilent also signed another agreement with “NCCS to provision biomarker testers for the research in molecular profiling of cancers.”